ArticleBMC cardiovascular disorders2026
Development and validation of a triglyceride-glucose index-based nomogram for predicting risk in STEMI patients undergoing primary PCI.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe triglyceride-glucose (TyG) index, a widely recognized surrogate marker of insulin resistance, has been extensively studied in the context of cardiovascular diseases. This study aimed to develop and validate a nomogram that predicts the prognosis of patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), utilizing the TyG index alongside readily available clinical data.
methodsThis retrospective study analyzed 1022 STEMI patients, divided into a training cohort (n = 715) and a validation cohort (n = 307). Potential risk factors were identified, and a predictive nomogram was constructed using least absolute shrinkage and selection operator (LASSO)-penalized Cox regression. Model performance was evaluated through receiver operating characteristic (ROC) curve analysis, calibration plots, Harrell's C-index, and decision curve analysis (DCA).
resultsThe nomogram incorporated five predictors: residual SYNTAX score (rSS), number of affected coronary vessels (VDn), high-sensitivity C-reactive protein (hsCRP), TyG index, and B-type natriuretic peptide (BNP). Harrell's C-index values of 0.73 (95% CI: 0.70-0.75) in the training cohort and 0.80 (95% CI: 0.76-0.83) in the validation cohort demonstrated strong discrimination. The area under the curve (AUC) for 1-year and 2-year major adverse cardiovascular events (MACE) predictions were 0.77 and 0.77 in the training cohort, and 0.86 and 0.85 in the validation cohort, highlighting excellent predictive accuracy. Subgroup analysis confirmed consistent model performance across age groups (< 65 years and ≥ 65 years), with AUC values ranging from 0.74 to 0.87. Calibration plots demonstrated excellent agreement between predicted and observed outcomes, and DCA highlighted the model's clinical utility by quantifying net benefits across a range of threshold probabilities.
conclusionsThis study developed and validated a novel predictive nomogram that integrates the TyG index with key inflammatory (hsCRP), anatomical (rSS and VDn), and functional (BNP) markers to stratify MACE risk in STEMI patients after PCI. The model demonstrated robust predictive performance and clinical utility, offering a practical tool for precise risk stratification and facilitating personalized treatment strategies to improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.